FROM

OFFICIAL

BRUMBAUGH, GRAVES, DONOHUE & RAYMOND 30 Rockefeller Plaza

New York, NY 10112 212-408-2500

Facsimile: 212-765-2519

FACSIMILE COVER <u>SHEE</u>

Date:

Fax No.

(708)<u>305-72</u>30

Deliver to:

Mr. Richard Schwartz

United States Patent and Trademark Office

From:

Rochelle K. Seide, Ph.D.

<u>(Ext. 2626)</u>

No. of Pages: 22 (including cover sheet)

For Assistance With

Facsimile Transmission: (212) 408-2662

MESSAGE:

!! URGENT !!

!! PLEASE DELIVER TO RICHARD SCHWARTZ IMMEDIATELY !!

Dear Richard:

As discussed, enclosed are copies of interference papers in reference to U.S. Serial No. 08/087,132.

Rochelle

(TO BE COMPLETED IN DUPLICATE)

The information contained in this facsimile message is intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service. Thank you.

FROM

4155-102US

The undersigned certifies that this communication is being deposited with the United States Postal Service as prepaid first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on December 27, 1996.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of GREGORY et al.

Serial No. 08/807,132 08/087, 132

Filed: July 2, 1993

For: NEW DIAGNOSTIC AND TREATMENT METHODS INVOLVING THE CYSTIC FIBROSIS TRANSMEMBRANE

REGULATOR

Group Art Unit: 1814

Examiner: K.C. Carlson, Ph.D.

Assistant Commissioner for Patents Washington, D. C. 20231

SIR:

SUPPLEMENTAL AMENDMENT AND REQUEST FOR INTERFERENCE UNDER 37 CFR §1.607

Further to Applicants' Response of August 6, 1996, kindly amend this application as follows:

Add new claims 226 and 227 reading as follows:

- 226. A recombinant vector comprising a DNA regulatory element operably linked to a DNA molecule that encodes a wild-type, human cystic fibrosis transmembrane conductance regulator protein, wherein the DNA molecule is capable of stable propagation in E. coli --